Skip to main content

DOSAGE AND ADMINISTRATION

Open Up a World
With Multiple Dosage and Administration Options

Offer your patients 6 years and older flexible administration: at home or in office1

Open Up a World
WITH MULTIPLE DOSAGE AND
ADMINISTRATION OPTIONS

Offer your patients 6 years and older flexible administration: at home or in office1

DUPIXENT is an injectable medicine that is administered by subcutaneous injection and is intended for use under the guidance of a healthcare provider.1
  • A patient may self-inject DUPIXENT—or a caregiver may administer DUPIXENT—after training has been provided by a healthcare provider on proper subcutaneous injection technique using the pre-filled syringe or pen
    • In children 12 years of age and older, it is recommended that DUPIXENT be administered under the supervision of an adult
  • It is important to provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use
  • After administration, advise patients to follow sharps disposal recommendations
  • Patients and/or caregivers should read the appropriate Instructions for Use prior to injecting

Dosage for adults/pediatric patients (12+ years)1

Adults/pediatric patients (12+ years) with moderate-to-severe asthma characterized by an eosinophilic phenotype of ≥150 cells/µL

The choice between a 600 mg loading dose with 300 mg biweekly dosing or a 400 mg loading dose with 200 mg biweekly dosing is at the discretion of the HCP and/or patient.

a300 mg=2 mL solution.

b200 mg=1.14 mL solution.

OCS-dependent asthma patients or patients with comorbid moderate-to-severe AD, CRSwNP, or AFRS1,c

  • Initial dose is 600 mg (two 300 mg pre-filled pens or syringes) followed by every-2-week dosing of a 300 mg pre-filled pen or syringe
cFor pediatric patients 12 years to 17 years of age (≥60 kg) and adults with AFRS

Dosage for children
(6 years to 11 years)1

Recommended weight-based
dosing for children aged 6 years to 11
years with uncontrolled moderate-
to-severe asthma

No loading dose.
d30 kg is equal to 66 lb.
e15 kg is equal to 33 lb.

For children (6 years to 11 years) with asthma and co-morbid moderate-to-severe atopic dermatitis, follow the recommended dosage for atopic dermatitis, which includes an initial loading dose.

  • In children 6 to less than 12 years of age, DUPIXENT should be given by a caregiver

Two administration options for you and your patients (6+ years)1-3

Important administration instructions1

  • Patients and/or caregivers should read the appropriate Instructions for Use prior to injecting
  • Instruct patients and/or caregivers to administer the subcutaneous injection into the thigh or abdomen, except for the 2 inches (5 cm) around the navel
  • The upper arm can also be used if a caregiver administers the injection
  • It is important to rotate the injection site with each injection. DO NOT inject DUPIXENT into skin that is tender, damaged, bruised, or scarred
  • See the Instructions for Use for more detailed instructions on the preparation and administration of DUPIXENT

Missed dose information1

  • If an every-2-week dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, instruct the patient to administer the dose, starting a new schedule based on this date
  • If an every-4-week dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient’s original schedule. If the missed dose is not administered within 7 days, instruct the patient to administer the dose, starting a new schedule based on this date

Preparation for use1

Before injection, instruct patients and/or caregivers to remove DUPIXENT from the refrigerator and allow DUPIXENT to reach room temperature without removing the needle cap.

  • 45 minutes for the 300 mg/2 mL pre‑filled syringe or pre-filled pen
  • 30 minutes for the 200 mg/1.14 mL pre‑filled syringe or pre-filled pen

Patients and/or caregivers should inspect DUPIXENT for particulate matter and discoloration prior to administration.

  • Do not use if the liquid contains visible particulate matter or is discolored or cloudy (other than clear to slightly opalescent, colorless to pale yellow)

Patients and/or caregivers should discard any unused product remaining in the pre‑filled syringe or pre-filled pen in accordance with local requirements.

Storage and handling1

  • DUPIXENT is sterile and preservative‑free. Patients and/or caregivers should discard any unused portion
  • Patients and/or caregivers should store DUPIXENT by refrigerating at 36 °F to 46 °F (2 °C to 8 °C) in the original carton to protect
    from light
  • If necessary, DUPIXENT may be kept at room temperature up to 77 °F (25 °C) for a maximum of 14 days. DUPIXENT should not
    be stored above 77 °F (25 °C). After removal from the refrigerator, DUPIXENT must be used within 14 days or discarded
  • DUPIXENT should not be exposed to heat or direct sunlight
  • Any unused medicinal product or waste material should be disposed of in accordance with local requirements
  • Do NOT freeze. Do NOT shake

AD, atopic dermatitis; AFRS, allergic fungal rhinosinusitis; CRSwNP, chronic rhinosinusitis with nasal polyps; OCS, oral corticosteroid.

DUPIXENT MyWay®

DUPXIENT MyWay is a patient support program that offers insurance coverage support, financial assistance, and resources to help eligible patients who are prescribed DUPIXENT.

EXPLORE PATIENT SUPPORT RESOURCES